Log In
Print
BCIQ
Print
Print this Print this
 

Campath-1H, alemtuzumab (Lemtrada, MabCampath, Campath)

Also known as: MabCampath-1H alemtuzumab (LDP-03)

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionHumanized mAb against CD52
Molecular Target CD52
Mechanism of ActionBinds CD52; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$26,800.0M

$20,100.0M

$3,800.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today